Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 12/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608053 | 0.94 | MCHR1 (0.40) | MCHR1ADRA2ANPY5RDDR1IDO1 | |
| SCHEMBL13608056 | 0.91 | IDO1 (0.46) | MCHR1ADRA2ANPY5RIDO1TDO2 | |
| SCHEMBL3847751 | 0.90 | MCHR1 (0.37) | MCHR1ADRA2ANPY5RDDR1EPHX2 | |
| SCHEMBL13620270 | 0.90 | MCHR1 (0.43) | MCHR1ADRA2ANPY5RDDR1 | |
| SCHEMBL13620211 | 0.88 | MCHR1 (0.41) | MCHR1ADRA2ANPY5RDDR1DRD2 | |
| SCHEMBL13620258 | 0.88 | MCHR1 (0.46) | MCHR1ADRA2ANPY5RDDR1 | |
| SCHEMBL13620375 | 0.88 | MCHR1 (0.46) | MCHR1ADRA2ANPY5RDDR1EPHX2 | |
| SCHEMBL13620269 | 0.88 | MCHR1 (0.46) | MCHR1ADRA2ANPY5RDDR1 | |
| SCHEMBL3844885 | 0.87 | USP1 (0.36) | DDR1IDO1TDO2DRD2DRD4 | |
| SCHEMBL13620385 | 0.86 | MCHR1 (0.44) | MCHR1ADRA2ANPY5RDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | MCHR1 3804/4885ADRA2A 461/4885NPY5R 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.